Want to catch up on the gossip from this year's Swiss Biotech Day? Now you can!
We were there in full force with our news team and we’ve made the articles from the day free to read, for a limited time, exclusively from our Scrip publication.
From Public Funds To VCs: Swiss Financing For Swiss Biotech
While most of the cash for Swiss biotech firms comes from outside the country, around 20% is provided by Swiss entities. Scrip spoke with two of these home-grown supporters of life sciences innovation about the move from academia to industry and their respective investment strategies.
Read the full articleSwiss Talent and Innovation ‘Needs More Financing To Flourish’
With excellent academic centers and a thriving start-up scene, Switzerland’s biotech scene has garnered significant interest in recent years. However, without being a priority for EU funds, the sector remains reliant on foreign cash and needs a funding push from within to boost success.
Read the full articleFrom Hengrui To Moderna: Why More Biotech Companies Are Creating Swiss Hubs
An increasing number of biotech companies originating from the US and Asia are building EU headquarters in Switzerland. Scrip spoke with four key opinion leaders on the motivations behind these decisions and the role the domestic ecosystem has to play, from school systems to neutral politics and beyond.
Read the full articleSwiss R&D Innovation: A Tale Of Two Firms Developing Cell Therapies For Wounds
While perhaps best known for historical achievements in immuno-oncology and CNS disorders, the Swiss biotech sector is slowly cultivating a new area of expertise in dermatology. Scrip spoke with two firms applying cell therapy technologies to the challenging area of chronic and acute wounds.
Read the full articleWant more from Scrip?
We've made it easier than ever for you to experince Scrip first-hand for leading Commercial news, interviews, and insights. Click below to register for a 7-day free trial.
START YOUR TRIAL